Search results
Results From The WOW.Com Content Network
Alpha-fetoprotein (AFP, α-fetoprotein; also sometimes called alpha-1-fetoprotein, alpha-fetoglobulin, or alpha fetal protein) is a protein [5] [6] that in humans is encoded by the AFP gene. [ 7 ] [ 8 ] The AFP gene is located on the q arm of chromosome 4 (4q13.3). [ 9 ]
It is a tetramer protein with 2 alpha and 2 gamma subunits. This is different from adult hemoglobin because it has 2 alpha and 2 beta subunits. Fetal hemoglobin is coded by a gene on chromosome 11. The gamma subunit on fetal hemoglobin contains a neutral and nonpolar amino acid at position 136, unlike the beta subunit of adult hemoglobin.
The major uterine and fetal glycoproteins that are associated with the eu-FEDS model in the human include alpha-fetoprotein, CA125, and glycodelin-A (also known as placental protein 14). Regulatory T cells also likely play a role. [11] Also, a shift from cell-mediated immunity toward humoral immunity is believed to occur. [12]
The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities (and neural tube defects). The term "multiple-marker screening test" is sometimes used instead.
The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Aoyagi, Y., et al. , Am. Cancer Soc., 83, 2076–2082, 1998. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transactheter arterial embolization.
An abdominal ultrasound every 3 months until at least eight years of age is recommended [10] and a blood test to measure alpha-fetoprotein (AFP) every 6 weeks until at least four years of age. [11] Families and physicians should determine screening schedules for specific patients, especially the age at which to discontinue screening, based upon ...
This is due to increased safety, increased sensitivity and decreased false positive rate of ultrasound as compared to MSAFP. [47] Amniotic fluid alpha-fetoprotein (AFAFP) and amniotic fluid acetylcholinesterase (AFAChE) tests are also used to confirming if ultrasound screening indicates a positive risk. [48]
As an example, Alpha-fetoprotein (AFP) testing is used to screen for a neural tube defect (NTD) during the second trimester of pregnancy. If the median AFP result at 16 weeks of gestation is 30 ng/mL and a pregnant woman's AFP result at that same gestational age is 60 ng/mL, then her MoM is equal to 60/30 = 2.0.